ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Moderna raises cash, invests in manufacturing

by Lisa M. Jarvis
September 12, 2016 | APPEARED IN VOLUME 94, ISSUE 36

The mRNA drug developer Moderna Therapeutics has closed yet another gargantuan round of funding. The $474 million in equity financing brings its total cash on hand to $1.4 billion. The money will be used to invest in its mRNA technology and support its growing clinical pipeline—two studies have begun and two more are near. Moderna also plans to build a $100 million manufacturing facility outside Boston to support the clinical trials. The biotech says it will unveil more details this fall.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment